Quick Answer
Acumen Pharmaceuticals, Inc. reported Operating Income of -$123.83 million for fiscal year 2025.
Acumen Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$123.83M | -8.6% |
| 2024 | -$114.02M | -86.5% |
| 2023 | -$61.14M | -35.2% |
| 2022 | -$45.24M | -131.0% |
| 2021 | -$19.58M | -147.5% |
| 2020 | -$7.91M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$26.51M | +17.8% | +36.5% |
| June 30, 2025 | -$41.75M | -71.2% | -37.5% |
| March 31, 2025 | -$30.37M | -70.9% | +5.9% |
| September 30, 2024 | -$32.27M | -101.2% | -32.3% |
| June 30, 2024 | -$24.38M | -80.9% | -37.2% |
| March 31, 2024 | -$17.77M | -35.3% | -10.8% |
| September 30, 2023 | -$16.04M | -41.1% | -19.0% |
| June 30, 2023 | -$13.48M | -29.5% | -2.6% |
- Acumen Pharmaceuticals, Inc. showed a decrease of -8.6% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Acumen Pharmaceuticals, Inc.’s operating income has declined by 1465.1% (from -$7.91 million to -$123.83 million).
- The most recent figure is from Acumen Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: